Investors Buy Large Volume of Call Options on Medline (NASDAQ:MDLN)

Medline (NASDAQ:MDLN) saw unusually large options trading on Monday. Stock traders bought 15,355 call options on the stock. This is an increase of approximately 423% compared to the average volume of 2,935 call options.

Institutional Investors Weigh In On Medline

A number of hedge funds have recently added to or reduced their stakes in the company. Carlyle Group Inc. purchased a new position in shares of Medline during the 4th quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in shares of Medline in the 4th quarter valued at approximately $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline in the fourth quarter valued at approximately $793,278,000. Morgan Stanley acquired a new position in Medline during the fourth quarter worth $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline during the fourth quarter worth $620,937,000.

Medline Stock Performance

Shares of MDLN opened at $42.48 on Tuesday. Medline has a 1 year low of $34.89 and a 1 year high of $50.88. The firm has a fifty day moving average price of $44.85.

Medline (NASDAQ:MDLN) last released its earnings results on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The firm’s revenue was up 14.8% on a year-over-year basis.

Analyst Ratings Changes

MDLN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medline in a research report on Monday, January 12th. They set a “hold” rating and a $40.00 target price on the stock. Morgan Stanley upped their price target on shares of Medline from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Royal Bank Of Canada raised their price objective on shares of Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Sanford C. Bernstein began coverage on shares of Medline in a research note on Monday, January 12th. They issued an “outperform” rating and a $49.00 price objective on the stock. Finally, UBS Group upped their target price on shares of Medline from $48.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.62.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.